Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data
- 30 April 2014
- journal article
- Published by Elsevier BV in European Urology
- Vol. 65 (4), 713-720
- https://doi.org/10.1016/j.eururo.2013.08.010
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and GrowthClinical Cancer Research, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- Tumour growth rates and RECIST criteria in early drug developmentEuropean Journal of Cancer, 2011
- Objective assessment of tumour response to therapy based on tumour growth kineticsBritish Journal of Cancer, 2011
- Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell CarcinomaThe Cancer Journal, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000